HomeCompareHGGCF vs JNJ

HGGCF vs JNJ: Dividend Comparison 2026

HGGCF yields 1000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HGGCF wins by $18844438.65M in total portfolio value
10 years
HGGCF
HGGCF
● Live price
1000.00%
Share price
$0.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18844438.68M
Annual income
$15,746,803,993,532.36
Full HGGCF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — HGGCF vs JNJ

📍 HGGCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHGGCFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HGGCF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HGGCF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HGGCF
Annual income on $10K today (after 15% tax)
$85,000.00/yr
After 10yr DRIP, annual income (after tax)
$13,384,783,394,502.51/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, HGGCF beats the other by $13,384,783,390,516.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HGGCF + JNJ for your $10,000?

HGGCF: 50%JNJ: 50%
100% JNJ50/50100% HGGCF
Portfolio after 10yr
$9422219.35M
Annual income
$7,873,401,999,110.88/yr
Blended yield
83.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

HGGCF
No analyst data
Altman Z
6.7
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HGGCF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHGGCFJNJ
Forward yield1000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$18844438.68M$30.3K
Annual income after 10y$15,746,803,993,532.36$4,689.40
Total dividends collected$18607754.73M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HGGCF vs JNJ ($10,000, DRIP)

YearHGGCF PortfolioHGGCF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$110,700$100,000.00$10,592$272.30+$100.1KHGGCF
2$1,153,028$1,034,579.44$11,289$357.73+$1.14MHGGCF
3$11,304,737$10,070,996.94$12,123$472.89+$11.29MHGGCF
4$104,376,400$92,280,331.11$13,141$629.86+$104.36MHGGCF
5$907,965,307$796,282,558.81$14,408$846.81+$907.95MHGGCF
6$7,445,190,031$6,473,667,152.78$16,021$1,151.60+$7445.17MHGGCF
7$57,576,798,154$49,610,444,821.11$18,122$1,588.22+$57576.78MHGGCF
8$420,166,535,918$358,559,361,892.40$20,930$2,228.20+$420166.51MHGGCF
9$2,894,985,686,808$2,445,407,493,376.48$24,792$3,191.91+$2894985.66MHGGCF
10$18,844,438,678,417$15,746,803,993,532.36$30,274$4,689.40+$18844438.65MHGGCF

HGGCF vs JNJ: Complete Analysis 2026

HGGCFStock

Highway 50 Gold Corp., an exploration stage company, engages in the acquisition, exploration, and evaluation of assets in North America. The company explores for Carlin-type gold deposits. Its projects portfolio includes the Gold Knob project comprises 687 unpatented claims located in Winnemucca, Nevada; the Golden Brew project that consists of 167 claims located in the Battle Mountain Mining District, Nevada; the Johnson Canyon project, which comprises 186 claims located in Lander County, Nevada; and the Monroe project covering an area of 1,282 hectares located in the Fort Steele Mining Division, Southeast British Columbia. The company was formerly known as Tatmar Ventures Inc. and changed its name to Highway 50 Gold Corp. in July 2011. Highway 50 Gold Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.

Full HGGCF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this HGGCF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HGGCF vs SCHDHGGCF vs JEPIHGGCF vs OHGGCF vs KOHGGCF vs MAINHGGCF vs ABBVHGGCF vs MRKHGGCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.